Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Thursday, March 4, 2021

Barriers to Voice Therapy in Dysphonic Children

xlomafota13 shared this article with you from Inoreader
The most common etiologies of dysphonia in the pediatric population are vocal fold nodules and muscle tension dysphonia. Vocal therapy is the first line treatment for these disorders in children. Despite this, not all children undergo therapy. The goal of this study is to examine how factors such as patient demographics and parental perceptions differ between children that choose to undergo or not to undergo voice therapy.
View on the web

O Tempora O Mores!

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Jan;108(1):1-2. doi: 10.1016/j.bulcan.2021.01.002.

NO ABSTRACT

PMID:33487219 | DOI:10.1016/j.bulcan.2021.01.002

View on the web

New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Jan 30:S0007-4551(21)00013-8. doi: 10.1016/j.bulcan.2020.12.005. Online ahead of print.

NO ABSTRACT

PMID:33531154 | DOI:10.1016/j.bulcan.2020.12.005

View on the web

New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Feb;108(2):142-144. doi: 10.1016/j.bulcan.2020.12.006. Epub 2021 Jan 30.

NO ABSTRACT

PMID:33531153 | DOI:10.1016/j.bulcan.2020.12.006

View on the web

New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Feb;108(2):139-140. doi: 10.1016/j.bulcan.2020.11.011. Epub 2021 Feb 2.

NO ABSTRACT

PMID:33546873 | DOI:10.1016/j.bulcan.2020.11.011

View on the web

Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Feb;108(2):140-142. doi: 10.1016/j.bulcan.2020.11.010. Epub 2021 Feb 3.

NO ABSTRACT

PMID:33546874 | DOI:10.1016/j.bulcan.2020.11.010

View on the web

How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Feb 17:S0007-4551(21)00036-9. doi: 10.1016/j.bulcan.2020.11.014. Online ahead of print.

ABSTRACT

Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant cells. In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta™) is the treatment of relapsed/refractory DLBCL and mediastinal B-cell lymphoma. Both products are "living drugs" and genetically modified autologous T cells directed against CD19 which is an antigen expressed throughout B lymphoid differentiation and on many B m alignancies. This collaborative work - part of a series of expert works on the topic - aims to provide practical advice to assist collection facilities that procure the starting material i.e. blood mononuclear cells for autologous CAR T-cell manufacturing.

PMID:33610284 | DOI:10.1016/j.bulcan.2020.11.014

View on the web

Cancer and communicational cancer: A squared cancer?

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Feb 19:S0007-4551(21)00017-5. doi: 10.1016/j.bulcan.2020.11.012. Online ahead of print.

NO ABSTRACT

PMID:33618822 | DOI:10.1016/j.bulcan.2020.11.012

View on the web

Experimental models in peritoneal dialysis (Review)

xlomafota13 shared this article with you from Inoreader

Exp Ther Med. 2021 Mar;21(3):240. doi: 10.3892/etm.2021.9671. Epub 2021 Jan 21.

ABSTRACT

Peritoneal dialysis (PD) is one of the most commonly used dialysis methods and plays an important role in maintaining the quality of life of patients with end-stage renal disease. However, long-term PD treatment is associated with adverse effects on the structure and function of peritoneal tissue, which may lead to peritoneal ultrafiltration failure, resulting in dialysis failure and eventually PD withdrawal. In order to prevent the occurrence of these effects, the important issues that need to be tackled are improvement of ultrafiltration, protection of peritoneal function and extension of dialysis time. In basic PD research, a reasonable experimental model is key to the smooth progress of experiments. A good PD model should not only simulate the process of human PD as accurately as possible, but also help researchers to understand the evolution p rocess and pathogenesis of various complications related to PD treatment. To better promote the clinical application of PD technology, the present review will summarize and evaluate the in vivo PD experimental models available, thus providing a reference for relevant PD research.

PMID:33603848 | PMC:PMC7851610 | DOI:10. 3892/etm.2021.9671

View on the web

Kidney aging process and the management of the elderly patient with renal impairment (Review)

xlomafota13 shared this article with you from Inoreader

Exp Ther Med. 2021 Mar;21(3):266. doi: 10.3892/etm.2021.9697. Epub 2021 Jan 25.

ABSTRACT

As life expectancy increases, a rise in the number of chronically ill patients is observed due to the aging population. Among the various diseases, chronic kidney disease is at present one of the main causes of morbidity and, due to its typical complications, it is also one of the most important causes of mortality in the general population. For these reasons, the understanding of the kidney aging process, its consequences and its adequate management are essential. The judicious use of certain types of drugs, the prevention of episodes of renal injury either by toxic mechanisms or by dehydration are important aspects and are part of the apropriate approach for elderly patients. The most effective treatment of various types of conditions with a negative impact on renal function and for which an increased incidence is known as we age should also be c onsidered. Thus, in the case of elderly patients, in order to protect the kidneys, an integrative approach is recommended, one that includes both elements of prevention and the appropriate treatment of existing diseases.

PMID:33603873 | PMC:PMC7851660 | DOI:10.3892/etm.2021.9697

View on the web

Discovering pathways in benign prostate hyperplasia: A functional genomics pilot study

xlomafota13 shared this article with you from Inoreader

Exp Ther Med. 2021 Mar;21(3):242. doi: 10.3892/etm.2021.9673. Epub 2021 Jan 22.

ABSTRACT

Benign prostate hyperplasia (BPH) is one of the well-known urological neoplasms common in males with an increasing number of associated deaths in aging males. It causes uncomfortable urinary symptoms, including urine flow blockage, and may cause bladder, urinary tract or kidney problems. The histopathological and clinical knowledge regarding BPH is limited. In the present study, an in silico approach was applied that uses genome-scale microarray expression data to discover a wide range of protein-protein interactions in addition to focusing on specific genes responsible for BPH to develop prognostic biomarkers. Various genes that were differentially expressed in BPH were identified. Gene and functional annotation clusters were determined and an interaction analysis with disease phenotypes of BPH was performed, as well as an RNA tissue specif icity analysis. Furthermore, a molecular docking study of certain short-listed gene biomarkers, namely anterior gradient 2 (AGR2; PDB ID: 2LNT), steroid 5α-reductase 2 (PDB ID: 6OQX), zinc finger protein 3 (PDB ID: 5T00) and collagen type XII α1 chain (PDB ID: 1U5M), was performed in order to identify alternative Chinese herbal agents for the treatment of BPH. Data from the present study revealed that AGR2 receptor (PDB ID: 2LNT) and berberine (Huang Bo) form the most stable complex and therefore may be assessed in further pharmacological studies for the treatment of BPH.

PMID:33603850 | PMC:PMC7851599 | DOI:10.3892/etm.2021.9673

View on the web

A finite element analysis for predicting outcomes of cemented total knee arthroplasty

xlomafota13 shared this article with you from Inoreader

Exp Ther Med. 2021 Mar;21(3):267. doi: 10.3892/etm.2021.9698. Epub 2021 Jan 25.

ABSTRACT

The study was designed to assess the validity of a finite element analysis for predicting the behavior of cemented knee implant used in total knee arthroplasty (TKA), for different mechanical loads, and correlation with clinical outcomes of this procedure. We conducted computational simulations using finite element analysis of two situations: i) The ideal prosthetic component positioning; and ii) variable varus tibial malposition, but with a balanced knee. A total of 80 cemented TKAs performed on 70 patients were divided into two groups. Patients from one group required secondary asymmetric tibial recut for balancing the prosthetic knee and patients from the other group, did not. In regards to the results, we observed no differences upon analysis of the postoperative results of the Knee Society Score (KSS), the angle between the femur and tibia, th e range of motion and frontal laxity between groups. The finite element analysis showed that in a 3˚ varus inclination of the joint interline, but with a balanced knee, the maximum contact stress, measured on the tibial plateau surface, increased by 11% compared to the value of mechanical alignment. In conclusion, analysis of the computational model using finite elements showed predictable results of cemented TKA for the different situations of mechanical loads.

PMID:33603874 | PMC:PMC7851662 | DOI:10.3892/etm.2021.9698

View on the web